CYP2D6 and the pharmacokinetics of ibogaine

Phase 1

Completed

• Conditions: Opioid dependence; Mental Health - Studies of normal psychology, cognitive function and behaviour

• Registration Number: ACTRN12613000324718
• Lead Sponsor: niversity of Otago

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-03-22
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

Healthy volunteers, drug free, good general health, normal screening lab tests and ECG

Exclusion Criteria

Significant medical history, drug use

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Plasma pharmacokinetics of ibogaine and its active metabolite[predose, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 and 168h]